Skip to content
HowShorted

HERON THERAPEUTICS, INC. short interest in 2022

In 2022, HERON THERAPEUTICS, INC.'s disclosed short interest ran from 36.26% of shares outstanding on 14 Jan 2022 to 21.05% on 30 Dec 2022, a change of -15.21 percentage points. The year's high was 39.45% on 29 Jul 2022 and its low 21.05% on 30 Dec 2022, averaging 32.76% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 22.85 days on 15 Feb 2022. Full history: HERON THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for HERON THERAPEUTICS, INC. in 2022

2022 in figures

Start of year
36.26% (14 Jan 2022)
End of year
21.05% (30 Dec 2022)
Change
-15.21 pp
High
39.45% (29 Jul 2022)
Low
21.05% (30 Dec 2022)
Average
32.76%
Highest days to cover
22.85 (15 Feb 2022)
SEC filings marked
8

Every report in 2022

HERON THERAPEUTICS, INC. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202236.26%21.85
31 Jan 202233.99%14.92
15 Feb 202234.50%22.85
28 Feb 202234.02%17.0510-K filed, results (8-K)
15 Mar 202233.14%10.46
31 Mar 202238.46%14.04
14 Apr 202236.42%18.93
29 Apr 202236.23%21.44
13 May 202236.08%10.8710-Q filed, results (8-K)
31 May 202236.07%17.03
15 Jun 202238.04%12.94
30 Jun 202235.56%11.84
15 Jul 202239.21%13.95
29 Jul 202239.45%21.33
15 Aug 202233.13%7.5410-Q filed, results (8-K)
31 Aug 202231.81%11.93
15 Sep 202231.88%9.79
30 Sep 202232.56%7.11
14 Oct 202228.43%14.19
31 Oct 202228.04%15.68
15 Nov 202223.89%10.2310-Q filed, results (8-K)
30 Nov 202223.74%15.15
15 Dec 202224.26%8.61
30 Dec 202221.05%6.76

See also: HERON THERAPEUTICS, INC.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.